Role of angiotensin II in cardiovascular disease - Therapeutic implications of more than a century of research

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 1, 2006, Pages 3-14

  Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Angiotensin II antagonists; Cardiovascular disease; Diabetes mellitus; Diabetic nephropathy; Hypertension; Post myocardial infarction; Stroke heart failure

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; SARALASIN; SPIRAPRIL; SPIRONOLACTONE; TEPROTIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; EVIDENCE BASED PRACTICE; HEART FAILURE; HEART INFARCTION; HORMONE ACTION; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33745150754     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.003     Document Type: Review

References (36)

1. Silverstein RL, Fenves AZ, Ram CV. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med 2004;116:31-8,41.
2. Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002;18:1331-9.
3. Nicholls MG, Robertson JI, Inagami T. The renin-Angiotensin system in the twenty-first century. Blood Press 2001;10:327-43.
4. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002;113:409-18.
5. Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci 2004;61:2720-7.
6. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(17) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005;289: H1560-H1566.
7. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
8. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31.
9. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
10. Swedberg K, Pfeffer M, Granger C et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. CHARM-Programme Investigators. J Card Fail 1999;5:276-82.
11. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
12. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
13. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
14. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
15. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
16. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
17. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the Angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
18. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
19. Nicholls MG, Robertson JI. The renin-angiotensin system in the year 2000. J Hum Hypertens 2000;14:649-66.
20. Roberston JIS. Epidemiology of the renin-angiotensin system in hypertension. In: Buipitt CJ, ed. Epidemiology of Hypertension Amsterdam: Elsevier, 2000:389-427.
21. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8.
22. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
23. Cohn JN, Tognoni G. A randomized trial of the Angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
24. Dahlof B, Burke TA, Krobot K, Carides GW, Edelman J, Devereux R. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial. J Hum Hypertens 2004;18:367-73.
25. Wachtell K, Hornestram B, Lehto M et al. Cardiovascular mortality and morbidity in hypertensive patients with atrial fibrillation: the LIFE trial. J Am Coll Cardiol 2005;45:705-11.
26. Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188-92.
27. Ibsen H, Wachtell K, Olsen MH et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004;22:1805-11.
28. Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE trial. Kidney Int 2004;65:1041-9.
29. Devereux RB, Dahlof B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-62.
30. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9.
31. Pepine CJ, Handberg, EM, Cooper-DeHoff RM et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
32. Edelman JM, Lyle PA, ZhAng Z. Letter to the editor. Ann Intern Med 2004;140:W-29.
33. Pitt B, Segal R, Martinez EA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
34. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
35. Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE trial. Lancet 2003;362:619-20.
36. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693-704.